Critical appraisal:Jiang J, Liang X, Zhou X, Huang R, Chu Z 2007 3

From Cancer Guidelines Wiki

Critical Appraisal

Article being appraised

Jiang J, Liang X, Zhou X, Huang R, Chu Z. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2007 Sep;57(3):348-58 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17485133.


Applicable clinical question

Key Facts

Study Design

systematic review — RCTs of carboplatin v cisplatin based chemotherapy

Number of Patients:

6906


Includes an economic evaluation

no

Evidence ratings

Level of evidence

I

Risk of bias
Low risk of bias Comments: Well conducted


Size of effect
3 Reason for decision: cisplatin-based regimens had a higher overall response rate in comparison with carboplatin-based regimens (RR, 0.91; 95%CI, 0.84—0.99; P = 0.02). However, the 1-year survival rate for the two platinum-based regimens were comparable (RR, 1.00, 95%CI, 0.94—1.07; P = 0.93). There was more nausea, vomiting and nephrotoxicity with cisplatin.
Relevance of evidence
1 Additional comments: OS, RR, QoL, toxicity
Result of appraisal

Jutta's tick icon.png Included




Completed by

Assoc. Prof. Nick Pavlakis


Jutta's tick icon.png This appraisal has been completed.


Article
Jiang J, Liang X, Zhou X, Huang R, Chu Z. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2007 Sep;57(3):348-58 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17485133.
Assigned to
User:Nick.pavlakis
Topic area
Guidelines:Lung cancer
Clinical question
Form
Form:Critical appraisal


Section below only relevant for Cancer Council Project Officer

Edit appraisal assignment